Jennifer Smith, MD
Family Medicine · Gig Harbor, WANPI 1215919170
Payments from drug & device makers
Across 130 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$356
- AbbVie$216
- AstraZeneca$211
- Amgen$205
- Lilly USA, LLC$197
- Novo Nordisk$167
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,548100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 16 | $356 |
| AbbVie(2 entities) | 14 | $216 |
| AstraZeneca | 10 | $211 |
| Amgen | 9 | $205 |
| Lilly USA, LLC | 11 | $197 |
| Novo Nordisk | 9 | $167 |
| Pfizer | 7 | $161 |
| Corcept Therapeutics | 3 | $97 |
| Bayer | 4 | $89 |
| Boehringer Ingelheim | 4 | $85 |
| Phathom Pharmaceuticals, Inc. | 8 | $70 |
| Astellas Pharma US Inc | 3 | $62 |
| Sanofi Pasteur Inc. | 3 | $60 |
| Insulet Corporation | 2 | $56 |
| Hologic Sales And Service, LLC | 3 | $53 |
| Irhythm Technologies, Inc. | 2 | $34 |
| Merck | 1 | $28 |
| Organogenesis Inc. | 1 | $25 |
| Phadia US Inc. | 1 | $24 |
| Vertex | 1 | $24 |
| Exact Sciences | 1 | $24 |
| Grifols USA, LLC | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $23 |
| Nevro Corp. | 1 | $23 |
| Seqirus USA Inc | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Boston Scientific | 1 | $20 |
| Kaleo, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Alkermes, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Mylan Specialty L.p. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$2,548 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 27 | $58,802 |
| OzempicSemaglutide | 37 | $53,360 |
| JardianceEmpagliflozin | 25 | $28,138 |
| XareltoRivaroxaban | 28 | $21,598 |
| EliquisApixaban | 15 | $10,668 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $10,526 |
| JanuviaSitagliptin Phosphate | 13 | $7,496 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,204 |
| Carvedilol ErCarvedilol Phosphate | 13 | $3,426 |
| Advair DiskusFluticasone Propion/Salmeterol | 16 | $3,108 |
| Atorvastatin Calcium | 210 | $2,446 |
| SynthroidLevothyroxine Sodium | 27 | $2,307 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 59 | $1,762 |
| Estradiol | 44 | $1,618 |
| Humulin RInsulin Regular, Human | 11 | $1,498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $197 | $58,80227 claims |
| Novo NordiskOzempic | $167 | $53,36037 claims |
| Boehringer IngelheimJardiance | $85 | $28,13825 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $356 | $14,73022 claims |
| PfizerEliquis | $161 | $10,66815 claims |
| MerckJanuvia | $28 | $7,49613 claims |
| AbbVieSynthroid | $216 | $2,30727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Gig Harbor
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
- Kevin HatfieldSeattle$527K
- Steven SmithAuburn$438K
- John RobinsonEdmonds$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.